Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19845815 | 0.92 | CA2 (0.52) | IDO1AGXTCA2CA9CA1 | |
| SCHEMBL249386 | 0.88 | CA2 (0.63) | IDO1AGXTCA2CA9CA1 | |
| Benzene SCHEMBL27447210 | 0.88 | CA2 (0.63) | IDO1AGXTCA2CA9CA1 | |
| SCHEMBL4952656 | 0.85 | CA2 (0.58) | AGXTCA2CA9CA1LMNA | |
| SCHEMBL14125769 | 0.85 | CA2 (0.61) | AGXTCA2CA9CA1LMNA | |
| SCHEMBL6279539 | 0.85 | UCHL1 (0.46) | IDO1AGXTCA2CA9CA1 | |
| SCHEMBL9502200 | 0.85 | CA2 (0.55) | IDO1CA2CA9CA1LMNA | |
| Formaldehyde SCHEMBL28740532 | 0.84 | CA2 (0.59) | IDO1AGXTCA2CA9CA1 | |
| Ethyne SCHEMBL28196610 | 0.84 | CA2 (0.59) | IDO1AGXTCA2CA9CA1 | |
| SCHEMBL3875829 | 0.83 | MEN1 (0.51) | CA2CA9CA1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551611-A1 | MONAMINE AND MONOAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10385007-B2 | Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| WO-2018107158-A1 | MONAMINE AND MONOAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180162802-A1 | MONAMINE AND MONOAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162802-A1 | MONAMINE AND MONOAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| CN-101362708-B | Synthesis method of tert-butyl- [2- (biphenyl-4-yl) -1- (hydroxymethyl) ethyl ] carbamate | UNIV ZHEJIANG TECHNOLOGY | 2012-05-16 | — | — | CN | disclosed |
| CN-101362708-A | Synthesis method of tert-butyl-[2-(biphenyl-4-yl)-1-(hydroxymethyl)ethyl] carbamate | UNIV ZHEJIANG TECHNOLOGY (CN) | 2009-02-11 | — | — | CN | disclosed |
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385007-B2 | Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, MAOB, LTB4R | IDO1 330/4885AGXT 2313/4885CA2 1854/4885 |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | IDO1 1102/4885AGXT 1160/4885CA2 656/4885 |
| US-20180162802-A1 | MONAMINE AND MONOAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, MAOB, LTB4R | IDO1 330/4885AGXT 2313/4885CA2 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.